(vianews) - essilorluxottica (el.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| essilorluxottica (el.pa) | €209.70 | 1.89% | 6.21% |
| vetoquinol (veto.pa) | €99.50 | 0.93% | 10.98% |
| virbac (virp.pa) | €346.00 | 0.38% | 13.84% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. essilorluxottica (el.pa)
1.89% forward dividend yield and 6.21% return on equity
essilorluxottica société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in europe, the middle east, africa, latin america, the asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the essilor, varilux, crizal, eyezen, stellest, xperio, transitions, ray-ban, oakley, barberini, kodak lens, nikon, shamir, eyexpert, iwear, humanware, and optifog brands. it also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the essilor instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the satisloh brand. in addition, the company provides eyewear products under the ray-ban, oakley, persol, oliver peoples, vogue eyewear, arnette, alain mikli, costa, bliz, native, luxottica, sferoflex, bolon, molsion, dbyd, and unofficial and seen, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.
earnings per share
as for profitability, essilorluxottica has a trailing twelve months eps of €5.08.
pe ratio
essilorluxottica has a trailing twelve months price to earnings ratio of 41.28. meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.21%.
moving average
essilorluxottica's value is above its 50-day moving average of €206.21 and above its 200-day moving average of €196.53.volatility
essilorluxottica's last week, last month's, and last quarter's current intraday variation average was 0.13%, 0.04%, and 1.03%.
essilorluxottica's highest amplitude of average volatility was 0.66% (last week), 0.64% (last month), and 1.03% (last quarter).
more news about essilorluxottica.
2. vetoquinol (veto.pa)
0.93% forward dividend yield and 10.98% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.02. meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.98%.
more news about vetoquinol.
3. virbac (virp.pa)
0.38% forward dividend yield and 13.84% return on equity
virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.
earnings per share
as for profitability, virbac has a trailing twelve months eps of €14.12.
pe ratio
virbac has a trailing twelve months price to earnings ratio of 24.5. meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.84%.
revenue growth
year-on-year quarterly revenue growth grew by 6.1%, now sitting on 1.25b for the twelve trailing months.
more news about virbac.